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Stem cell factor (SCF) activates hematopoietic stem cell (HSC) self-renewal and is being used to stimulate the
ex vivo expansion of HSCs. The mechanism by which SCF supports expansion of HSCs remains poorly understood.
In cord blood ex vivo expansion assays, a newly produced anti-SCF monoclonal antibody (clone 23C8) was found
to significantly inhibit the expansion of CD34+ cells. This antibody appears to bind directly to a part of SCF that is
critical for biological activity toward expansion of CD34+ cells, which is located in the first 104 amino acids from the
NH2-terminus.
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The stem cell factor (SCF) is a principal cytokine
involved in the expansion and differentiation of
hematopoietic stem cells (HSCs) [1]. The combined use
of SCF and other cytokines can effectively stimulate the
ex vivo expansion of umbilical cord blood CD34+ cells
[2-4]. The mechanisms of SCF’s action on HSCs are un-
known. A better understanding of SCF’s action may help
to further optimize systems for ex vivo expansion of
HSCs.
Using a prokaryotic expression system, we obtained re-
combinant human SCF (rhSCF) for preparation of
monoclonal antibodies (mAb) [5]. A specific mAb cell
line (23C8) was identified, and utilized for studies on
rhSCF. As shown in Table 1, rhSCF caused significant
increases in CD34+ cell expansion index. When 23C8
was added together with rhSCF, the expansion index was
reduced in an antibody concentration-dependent man-
ner; at a molar ratio of mAb to rhSCF equal to or higher
than 0.5, the activity of rhSCF was completely blocked.
Thus, binding of 23C8 to rhSCF leads to inhibition of
rhSCF’s biological activity.* Correspondence: yjiang@biopharmagen.com
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reproduction in any medium, provided the orFour bands (A-D) were detected when purified rhSCF
was first subjected to limited proteolysis with trypsin and
then analyzed by SDS-PAGE (Figure 1). Band A had the
same size as intact rhSCF (19 kD), whereas bands B-D
represented three tryptic fragments. Bands B (~15 kD)
and C (~12 kD), as well as band A, were detected on
Western blots using mAb 23C8, while band D (<6 kD)
was not detected. Amino-terminal sequence analysis
indicated that B and C both contained the amino
terminus of rhSCF. A computer analysis of SCF protein
sequence revealed putative trypsin cleavage sites between
residues 128 and 129 (yielding a ~15-kD fragment, corre-
sponding to B) and between 104 and 105 (yielding a ~12-
kD fragment, corresponding to C). Therefore, we con-
clude that fragment C contained the amino acids 1-104
of SCF.
In summary, we show that mAb 23C8 can neutralize
the activity of rhSCF, apparently through direct binding
to a part of rhSCF located within the first 104 amino
acids from the NH2-terminus. Our novel findings will be
valuable for further mechanistic dissection and optimization
of the ex vivo expansion of HSCs.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.









+ (reference)a None 0 17.50 ± 1.50 31.44 ± 1.68 6.50 ± 0.87#
Noneb None 0 5.00 ± 0.50 31.65 ± 0.50 1.87 ± 0.21*
+ Buffer onlyc 0 17.83 ± 0.58 29.12 ± 2.06 6.11 ± 0.41#
+ + 0.25 9.90 ± 0.93 31.64 ± 2.38 3.67 ± 0.09*#
+ + 0.50 5.00 ± 1.00 30.66 ± 0.39 1.80 ± 0.34*
+ + 1.0 4.50 ± 1.00 26.16 ± 1.27 1.39 ± 0.35*
+ + 2.0 4.50 ± 1.32 28.52 ± 4.41 1.52 ± 0.50*
+ + 5.0 4.67 ± 1.44 29.95 ± 4.00 1.60 ± 0.33*
+ + 10 4.25 ± 0.43 28.38 ± 1.71 1.43 ± 0.22*
Each well was added with umbilical cord blood MNC (~7.3 × 104, containing 11.63% CD34+ cells), in 0.5 ml of STEM PROW-34SFM medium containing 50 ng/ml
rhTPO and 200 ng/ml rhFL on day 1. Additional reagents were added to various groups, as indicated, including 200 ng/ml reference rhSCF or rhSCF produced
in-house, and mAb buffer alone or anti-rhSCF mAb added at different amounts. Cells were cultured at 37°C, with humidified air containing 5% CO2, for 7 days.
Culture medium was replenished on day 3. Data represent means ± SD, n = 3. CD34+ expansion index is defined as the fold increase [(after expansion)/(before




*, P < 0.05, compared with vehicle control and positive control.
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Figure 1 Detection of tryptic peptides of rhSCF that contain
the epitope recognized by the anti-rhSCF mAb. Reaction
mixtures of tryptic digest of rhSCF were analyzed on SDS-PAGE and
stained with Coomassie Blue (top) to visualize total protein, or on a
Western blot (bottom) using the anti-rhSCF mAb (clone 23C8). Lanes
1–5, purified rhSCF digested with trypsin for 0.5, 1, 2, 4, and 6 h,
respectively. The intact protein (A) and three proteolytic products
(C-D) are indicated; D was not recognized by the anti-rhSCF mAb.
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